Data gathered: May 17
Alternative Data for Arcus Biosciences
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 17 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 14,000 | Sign up | Sign up | Sign up |
| Employee Rating | 72 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 2 | Sign up | Sign up | Sign up |
| Facebook Followers | 35 | Sign up | Sign up | Sign up |
| Instagram Followers | 39 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 1,407 | Sign up | Sign up | Sign up |
| Twitter Followers | 1,052 | Sign up | Sign up | Sign up |
| Twitter Mentions | 13 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 69 | Sign up | Sign up | Sign up |
| Linkedin Employees | 578 | Sign up | Sign up | Sign up |
About Arcus Biosciences
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.
| Price | $17.46 |
| Target Price | Sign up |
| Volume | 612,090 |
| Market Cap | $1.6B |
| Year Range | $13.43 - $21.38 |
| Dividend Yield | 0% |
| Industry | Biotechnology |
In the news
 |
Arcus Biosciences: A Preview Of Their Outlook Ahead Of ASCOMay 14 - SeekingAlpha |
 |
Wedbush Weighs in on Arcus Biosciences, Inc.’s Q2 2024 Earnings (NYSE:RCUS)May 13 - ETF Daily News |
Optimistic Buy Rating for Arcus Biosciences Based on Promising Efficacy and Safety Profile of DomvanalimabMay 12 - TipRanks |
|
Buy Rating on Arcus Biosciences: Unique Anti-TIGIT Antibody and Promising Cancer Trials Fuel OptimismMay 12 - TipRanks |
|
 |
Arcus Biosciences, Inc. (NYSE:RCUS) Reported Earnings Last Week And Analysts Are Already Upgrading Their EstimatesMay 12 - Yahoo Entertainment |
|
Research Analysts Set Expectations for Arcus Biosciences, Inc.’s Q1 2025 Earnings (NYSE:RCUS)May 12 - ETF Daily News |
Insider Transactions View All
| Jarrett Jennifer filed to sell 215,253 shares at $17.6. March 29 '24 |
| Jarrett Jennifer filed to sell 226,804 shares at $18.6. March 20 '24 |
| Jarrett Jennifer filed to sell 228,100 shares at $17.8. March 20 '24 |
| Jaen Juan C. filed to sell 1,188,233 shares at $20.1. February 28 '24 |
| Jarrett Jennifer filed to sell 240,253 shares at $20.1. February 28 '24 |
Similar companies
Read more about Arcus Biosciences (RCUS) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Arcus Biosciences?
The Market Cap of Arcus Biosciences is $1.6B.
What is the current stock price of Arcus Biosciences?
Currently, the price of one share of Arcus Biosciences stock is $17.46.
How can I analyze the RCUS stock price chart for investment decisions?
The RCUS stock price chart above provides a comprehensive visual representation of Arcus Biosciences' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Arcus Biosciences shares. Our platform offers an up-to-date RCUS stock price chart, along with technical data analysis and alternative data insights.
Does RCUS offer dividends to its shareholders?
As of our latest update, Arcus Biosciences (RCUS) does not offer dividends to its shareholders. Investors interested in Arcus Biosciences should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Arcus Biosciences?
Some of the similar stocks of Arcus Biosciences are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.